Given the association of TGF-β1 with poor survival in advanced PDAC (50) and poor response to checkpoint blockade in metastatic cancers (51), TGF-β1 may be an appropriate target for therapeutic intervention in PC, particularly at the advanced stage. Here, TGFB1 is linked to metastatic malignant neoplasm.